AT-1501 Market Summary

Key Factors Driving AT-1501 Growth

1. Potential to replace calcineurin-inhibitor-based immunosuppression: AT-1501, now called tegoprubart, is a humanized anti-CD40L monoclonal antibody designed to block the CD40/CD40L costimulatory pathway without directly depleting lymphocytes. Its lead opportunity is kidney transplantation, where it is being developed as an alternative to tacrolimus. This is important because chronic calcineurin-inhibitor exposure can contribute to nephrotoxicity and other complications. Eledon is specifically developing tegoprubart as a potential CNI-free immunosuppression regimen.

2. Positive Phase 2 BESTOW data: The Phase II BESTOW trial enrolled 120 kidney-transplant recipients and compared tegoprubart with tacrolimus. Long-term data presented in June 2026 showed that at month 18, mean eGFR was approximately 74 vs. 61 mL/min/1.73 m², a statistically significant ~12 mL/min/1.73 m² advantage for tegoprubart. No biopsy-proven acute rejection events occurred in the tegoprubart group after the first six months, compared with seven events (9.4%) in the tacrolimus arm. These findings provide an important clinical basis for further development.

3. Encouraging long-term kidney-transplant data: Earlier Phase Ib follow-up also supports the durability of the program. Among eight patients followed for 24 months, Eledon reported no biopsy-proven acute rejection, graft loss, death, new-onset diabetes, or de-novo donor-specific antibodies, while mean eGFR increased from 67.0 at 12 months to 74.2 mL/min/1.73 m² at 24 months. Although the small sample size limits interpretation, these results strengthen the rationale for larger trials.

4. Potential expansion into islet transplantation and Type 1 diabetes: Tegoprubart's opportunity extends beyond kidney transplantation. In a University of Chicago investigator-led islet-transplant study, all 12 treated patients achieved insulin independence, with all 12 also achieving HbA1c below 6.5%; no severe hypoglycemic episodes were reported after transplantation. Eledon is pursuing regulatory discussions concerning a potential pathway to market for islet-cell transplantation, creating a second potential commercial application.

5. Broader transplantation-platform potential: Tegoprubart is also being used as an immunosuppressive component in xenotransplantation, including genetically modified pig-kidney-to-human transplants conducted at Massachusetts General Hospital. In addition, the FDA granted tegoprubart Orphan Drug designation for prevention of allograft rejection in liver transplantation in March 2026. These programs could expand the eventual addressable population if clinical efficacy and safety are established.

AT-1501 Recent Developments

In March 2026, Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the Advanced Technologies and Treatments for Diabetes (ATTD) conference.

“AT-1501 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of AT-1501 for potential indication like Allotransplant rejection, Amyotrophic lateral sclerosis, Renal transplant rejection, Islet cell transplant rejection, and Xenotransplant rejection in the 7MM. A detailed picture of AT-1501’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the AT-1501 for potential indications. The AT-1501 market report provides insights about AT-1501’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current AT-1501 performance, future market assessments inclusive of the AT-1501 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of AT-1501 sales forecasts, along with factors driving its market.

AT-1501 Drug Summary

AT-1501, now known as tegoprubart, is an investigational, engineered humanized monoclonal antibody targeting CD40 ligand (CD40L) and is being developed as an immunomodulatory therapy for transplantation and immune-mediated diseases, including kidney transplantation, pancreatic islet-cell transplantation, and amyotrophic lateral sclerosis (ALS). The antibody binds to CD40L and blocks CD40L-mediated costimulatory signaling between activated T cells and antigen-presenting cells, thereby reducing T-cell activation and downstream immune responses while potentially promoting a more tolerogenic immune environment. AT-1501 was specifically engineered to lack Fc-effector function, with the aim of avoiding Fcγ-receptor-mediated platelet activation and the thromboembolic complications associated with earlier anti-CD40L antibodies. The drug is administered by intravenous infusion and has demonstrated clinical development across multiple indications; Phase I studies evaluated its safety, pharmacokinetics, and tolerability in healthy volunteers and adults with ALS, while subsequent studies have investigated its potential to reduce or replace calcineurin-inhibitor-based immunosuppression following kidney or islet transplantation. In kidney transplantation, the Phase II BESTOW study is evaluating tegoprubart against tacrolimus for prevention of rejection, while an ongoing clinical study is also evaluating AT-1501 in combination with transplanted pancreatic islet cells in adults with difficult-to-control type 1 diabetes. AT-1501 remains investigational and is not approved for routine clinical use. The report provides AT-1501’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the AT-1501 Market Report

The report provides insights into:

• A comprehensive product overview including the AT-1501 MoA, description, dosage and administration, research and development activities in potential indication like Allotransplant rejection, Amyotrophic lateral sclerosis, Renal transplant rejection, Islet cell transplant rejection, and Xenotransplant rejection.
• Elaborated details on AT-1501 regulatory milestones and other development activities have been provided in AT-1501 market report.
• The report also highlights AT-1501‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The AT-1501 market report also covers the patents information, generic entry and impact on cost cut.
• The AT-1501 market report contains current and forecasted AT-1501 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The AT-1501 market report also features the SWOT analysis with analyst views for AT-1501 in potential indications.

Methodology

The AT-1501 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AT-1501 Analytical Perspective by DelveInsight

• In-depth AT-1501 Market Assessment

This AT-1501 sales market forecast report provides a detailed market assessment of AT-1501 for potential indication like Allotransplant rejection, Amyotrophic lateral sclerosis, Renal transplant rejection, Islet cell transplant rejection, and Xenotransplant rejection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted AT-1501 sales data uptil 2034.

• AT-1501 Clinical Assessment

The AT-1501 market report provides the clinical trials information of AT-1501 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

AT-1501 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

AT-1501 Market Potential & Revenue Forecast

• Projected market size for the AT-1501 and its key indications
• Estimated AT-1501 sales potential (AT-1501 peak sales forecasts)
• AT-1501 Pricing strategies and reimbursement landscape

AT-1501 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• AT-1501 Market positioning compared to existing treatments
• AT-1501 Strengths & weaknesses relative to competitors

AT-1501 Regulatory & Commercial Milestones

• AT-1501 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

AT-1501 Clinical Differentiation

• AT-1501 Efficacy & safety advantages over existing drugs
• AT-1501 Unique selling points

AT-1501 Market Report Highlights

• In the coming years, the AT-1501 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The AT-1501 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AT-1501’s dominance.
• Other emerging products for Allotransplant rejection, Amyotrophic lateral sclerosis, Renal transplant rejection, Islet cell transplant rejection, and Xenotransplant rejection are expected to give tough market competition to AT-1501 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AT-1501 in potential indications.
• Analyse AT-1501 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted AT-1501 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AT-1501 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of AT-1501? How strong is AT-1501’s clinical and commercial performance?
• What is AT-1501’s clinical trial status in each individual indications such as Allotransplant rejection, Amyotrophic lateral sclerosis, Renal transplant rejection, Islet cell transplant rejection, and Xenotransplant rejection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AT-1501 Manufacturers?
• What are the key designations that have been granted to AT-1501 for potential indications? How are they going to impact AT-1501’s penetration in various geographies?
• What is the current and forecasted AT-1501 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of AT-1501 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to AT-1501 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is AT-1501? What is the duration of therapy and what are the geographical variations in cost per patient?